See the DrugPatentWatch profile for lurbinectedin

Lurbinectedin is an antineoplastic agent, used for the treatment of various types of cancer in adults. However, the available information does not provide specific guidance on how lurbinectedin is administered to infants. In general, the administration of medications to infants is determined by a healthcare professional, taking into account factors such as the infant's age, weight, overall health, and the specific condition being treated.

Lurbinectedin is administered intravenously, typically over the course of several hours, and the dosage is usually calculated based on the patient's body surface area. However, it is important to note that the use of lurbinectedin in infants is not approved by regulatory agencies such as the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

Therefore, it is crucial that any decision to administer lurbinectedin to an infant is made by a qualified healthcare professional, taking into account all relevant information and guidelines.

Sources:

1. [Lurbinectedin (pegylated) for injection, for intravenous use](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761157s000lbl.pdf)
2. [Lurbinectedin](https://www.drugs.com/mtm/lurbinectedin.html)
3. [Lurbinectedin (pegylated)](https://www.ema.europa.eu/en/medicines/human/EPAR/zepzelca)
4. [Lurbinectedin](https://www.drugpatentwatch.com/drugs/lurbinectedin)